Growth Hormone-Releasing Hormone Analogs Protect Against Colitis in Mice
Both a GHRH antagonist (MIA-690) and a GHRH agonist (MR-409) reduced inflammation, tissue damage, and pain in a mouse model of colitis, with the antagonist showing stronger anti-inflammatory effects linked to lower IGF-1 levels.
Quick Facts
What This Study Found
Both GHRH analogs — the antagonist MIA-690 and the agonist MR-409 — attenuated DSS-induced colitis in mice, improving clinical symptoms and reducing histopathological damage.
In ex vivo colon tissue, both peptides inhibited production of pro-inflammatory and oxidative markers triggered by bacterial toxin (LPS). In live mice, both reduced pain responses in hot plate and formalin tests and decreased sensitivity to inflammatory stimuli.
MIA-690 showed superior efficacy compared to MR-409, more strongly inhibiting prostaglandin E2, 8-iso-PGF2α, serotonin, TNF-α, IL-6, and nitric oxide synthase gene expression in colitis-affected colon tissue. MIA-690 also uniquely decreased serum IGF-1 levels in colitis mice, which may explain its stronger anti-inflammatory and antioxidant activity.
Key Numbers
MIA-690 reduced PGE2, 8-iso-PGF2α, 5-HT, TNF-α, IL-6, iNOS, and serum IGF-1; both analogs reduced pain and clinical symptoms; MIA-690 showed higher efficacy than MR-409
How They Did This
Researchers used both ex vivo and in vivo approaches. Isolated mouse colon specimens were exposed to bacterial lipopolysaccharide (LPS) to trigger inflammation, then treated with MIA-690 or MR-409. In live male mice, colitis was induced using dextran sodium sulfate (DSS) in drinking water. Peptides were administered subcutaneously. Pain sensitivity was assessed using hot plate and formalin tests. The team measured clinical colitis symptoms, histopathological tissue damage, inflammatory markers (PGE2, TNF-α, IL-6, iNOS), oxidative stress markers (8-iso-PGF2α), serotonin levels, and serum IGF-1.
Why This Research Matters
Current treatments for inflammatory bowel disease often have significant side effects and don't work for all patients. GHRH analogs represent a completely different therapeutic approach — targeting hormonal pathways rather than the immune system directly. The finding that both an agonist and antagonist of the same hormone receptor can reduce gut inflammation suggests a complex regulatory mechanism that could open new treatment avenues.
The Bigger Picture
Inflammatory bowel disease affects millions globally, and the search for better treatments with fewer side effects continues. This study adds to growing evidence that peptide hormones involved in growth and metabolism also play important roles in regulating inflammation. If GHRH analogs prove effective in humans, they could complement or offer alternatives to current immunosuppressive therapies for conditions like ulcerative colitis and Crohn's disease.
What This Study Doesn't Tell Us
This is an animal study using a chemical model of colitis (DSS), which does not fully replicate the complexity of human inflammatory bowel disease. The study was short-term, so long-term effects and safety are unknown. Specific dosages and group sizes are not reported in the abstract. There was no comparison to standard colitis treatments like aminosalicylates or biologics, making it hard to judge relative effectiveness.
Questions This Raises
- ?Why do both a GHRH agonist and antagonist produce anti-inflammatory effects — does this suggest the mechanism is independent of classical GHRH receptor signaling?
- ?Would GHRH analogs be effective in other forms of inflammatory bowel disease beyond chemically induced colitis?
- ?Could the IGF-1 lowering effect of MIA-690 have unintended consequences with long-term use?
Trust & Context
- Key Stat:
- 6+ inflammatory markers reduced MIA-690 significantly lowered PGE2, 8-iso-PGF2α, serotonin, TNF-α, IL-6, and iNOS expression in colitis-affected colon tissue, alongside reducing serum IGF-1.
- Evidence Grade:
- This is a preliminary animal study using a chemically induced colitis model in mice. While the results are promising and consistent across multiple endpoints, animal models do not reliably predict human outcomes, and key details like sample sizes are not reported. Significant further research including human trials would be needed.
- Study Age:
- Published in 2021, this is a relatively recent study. GHRH analogs remain an active area of research, and follow-up studies may have since expanded on these findings.
- Original Title:
- Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice.
- Published In:
- Scientific reports, 11(1), 2530 (2021)
- Authors:
- Recinella, Lucia(5), Chiavaroli, Annalisa(5), Di Valerio, Valentina(2), Veschi, Serena, Orlando, Giustino, Ferrante, Claudio, Gesmundo, Iacopo, Granata, Riccarda, Cai, Renzhi, Sha, Wei, Schally, Andrew V, Lattanzio, Rossano, Brunetti, Luigi, Leone, Sheila
- Database ID:
- RPEP-05716
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How can both a GHRH blocker and activator reduce inflammation?
This is a surprising finding. It may mean that GHRH analogs exert anti-inflammatory effects through pathways beyond simple receptor activation or blockade — possibly involving IGF-1 regulation, direct effects on immune cells, or interactions with other receptor systems. The antagonist's stronger effect correlated with its ability to lower IGF-1, suggesting that pathway may be particularly important.
Could GHRH peptides become a treatment for inflammatory bowel disease in humans?
It's too early to say. This mouse study provides promising initial evidence, but animal models of colitis don't perfectly mirror human IBD. Clinical trials in humans would be needed to determine safety, dosing, and whether the anti-inflammatory effects translate across species. Currently, GHRH analogs are not approved for any inflammatory condition.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05716APA
Recinella, Lucia; Chiavaroli, Annalisa; Di Valerio, Valentina; Veschi, Serena; Orlando, Giustino; Ferrante, Claudio; Gesmundo, Iacopo; Granata, Riccarda; Cai, Renzhi; Sha, Wei; Schally, Andrew V; Lattanzio, Rossano; Brunetti, Luigi; Leone, Sheila. (2021). Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice.. Scientific reports, 11(1), 2530. https://doi.org/10.1038/s41598-021-81778-4
MLA
Recinella, Lucia, et al. "Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice.." Scientific reports, 2021. https://doi.org/10.1038/s41598-021-81778-4
RethinkPeptides
RethinkPeptides Research Database. "Protective effects of growth hormone-releasing hormone analo..." RPEP-05716. Retrieved from https://rethinkpeptides.com/research/recinella-2021-protective-effects-of-growth
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.